LOGO
LOGO

Quick Facts

SOPHiA GENETICS Expands Partnership With AstraZeneca To Optimize Outcomes For Breast Cancer Patients

By RTTNews Staff Writer   ✉   | Published:   | Follow Us On Google News

SOPHiA GENETICS SA (SOPH), Tuesday announced an expansion of collaboration with AstraZeneca (AZN), expecting to leverage its multimodal AI Factories to generate evidence on the efficacy, value, and real-world impact of therapies for certain types of breast cancer.

Moreover, it will also support the potential development of a bespoke AI-powered predictive model aimed at optimizing outcomes for individuals undergoing treatment for breast cancer.

The expanded partnership is expected to position SOPHiA as a trusted technology partner and underlines its commitment to advancing global health through federated data analytics and artificial intelligence.

In the pre-market hours, SOPH is moving down 4.5 percent, to $3.15 on the Nasdaq.

For comments and feedback contact: editorial@rttnews.com

Business News

Get Access to Premium Stock Alerts with RTT Biotech Investor.
Global Economics Weekly Update - April 27 – May 01, 2026

May 01, 2026 15:54 ET
Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.

Latest Updates on COVID-19